Government Slashes Prices: 30 Essential Medicines, Including Vitamin D3 & Methylcobalamin, Get New MRPs

In a move that many patients will welcome, the Ministry of Health and Family Welfare announced yesterday that the maximum retail prices (MRPs) for thirty essential medicines have been revised. Among the drugs getting a price tag overhaul are the familiar supplements Vitamin D3 (cholecalciferol) and methylcobalamin – a form of Vitamin B12 often prescribed for nerve health.

The decision comes after a series of consultations with pharma manufacturers, consumer groups and medical experts. Officials say the goal is simple: keep life‑saving and routine medicines within reach of ordinary citizens, especially in rural and low‑income areas where even a modest price hike can be a big deal.

“We understand the anxiety people feel when the cost of a single bottle of Vitamin D3 climbs,” explained a senior health ministry official during a brief press conference. “By setting a clear, affordable ceiling, we hope to remove that worry and let doctors focus on treatment, not cost.”

For methylcobalamin, which is frequently used to treat peripheral neuropathy and certain types of anemia, the new MRP represents a modest reduction of about 8 % compared with the previous average market price. The exact figure will appear on the updated price list that the ministry plans to circulate to pharmacies and drug distributors by the end of the month.

Pharma companies have expressed mixed reactions. While some welcome the clarity and predictability of a government‑mandated ceiling, others worry about squeezing profit margins, especially for drugs that require sophisticated manufacturing processes. Still, most agree that a stable pricing environment could benefit everyone in the long run – manufacturers, retailers, and most importantly, patients.

Consumers can expect to see the new MRPs reflected on medicine shelves within two weeks, according to the ministry’s rollout schedule. The authorities have also promised strict enforcement, with regular audits and hefty penalties for retailers who charge above the stipulated ceiling.

Overall, the price revision is part of a broader effort to make essential healthcare more affordable across the country. It joins earlier initiatives that capped prices for anti‑diabetic drugs, antihypertensives and several antibiotics. The hope is that, over time, such measures will reduce out‑of‑pocket expenses and improve treatment adherence among the most vulnerable.